Danaher Corporation reported strong Q3 earnings with revenue up 8.3% year-over-year to $6.55 billion and adjusted EPS of $2.11, driven by growth in its Diagnostics segment. However, challenges remain from volatile respiratory revenue and pricing pressures due to China's volume-based procurement. The stock trades at a small premium with a price to free cash flow ratio near 30, above its 5-year average of 27.7, leading to a Hold rating as the expected return of 8.85% is below the analyst's threshold. Investors should watch for how the company navigates these headwinds going forward.
Danaher Corporation shares show steady interest on Pluang, with 88% of order activity on the buy side and a slight 0.01% price increase. The stock trades at USD 234.11, close to its 52-week high of USD 242.05. These figures are current as of Oct 22, 2026 18:12 WIB.
Danaher Corporation reported Q3 results showing an 8.3% year-over-year revenue increase, primarily driven by acquisitions and tariff refunds rather than organic growth. The company achieved an adjusted operating margin of 29%, surpassing guidance, bu...
Danaher reported Q3 2026 earnings per share of $2.11, surpassing analyst estimates of $1.92, although revenue slightly missed expectations at $6.55 billion versus $6.56 billion forecast. The company highlighted improving customer demand and faster co...
Danaher Corporation reported strong Q3 2026 results with net earnings rising 34.5% year-over-year to $1.2 billion, or $1.71 per diluted share. Revenues increased 8.5% to $6.6 billion, driven by core growth excluding respiratory revenue. The company r...
